[HTML] frontiersin.org

[HTML][HTML] The NLRP3 inflammasome in non-alcoholic fatty liver disease and steatohepatitis: Therapeutic targets and treatment

L Yu, W Hong, S Lu, Y Li, Y Guan, X Weng… - Frontiers in …, 2022 - frontiersin.org
Non-alcoholic fatty liver disease (NAFLD) is among the most prevalent primary liver
diseases worldwide and can develop into various conditions, ranging from simple steatosis …
被引用次数：66 相关文章

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment

L Yu, W Hong, S Lu, Y Li, Y Guan… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
Non-alcoholic fatty liver disease (NAFLD) is among the most prevalent primary liver
diseases worldwide and can develop into various conditions, ranging from simple steatosis …

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment.

L Yu, W Hong, S Lu, Y Li, Y Guan, X Weng… - Frontiers in …, 2022 - europepmc.org
Non-alcoholic fatty liver disease (NAFLD) is among the most prevalent primary liver
diseases worldwide and can develop into various conditions, ranging from simple steatosis …
[HTML] nih.gov

[HTML][HTML] The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment

L Yu, W Hong, S Lu, Y Li, Y Guan, X Weng… - Frontiers in …, 2022 - ncbi.nlm.nih.gov
Non-alcoholic fatty liver disease (NAFLD) is among the most prevalent primary liver
diseases worldwide and can develop into various conditions, ranging from simple steatosis …

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment.

L Yu, W Hong, S Lu, Y Li, Y Guan, X Weng… - Frontiers in …, 2022 - europepmc.org
Non-alcoholic fatty liver disease (NAFLD) is among the most prevalent primary liver
diseases worldwide and can develop into various conditions, ranging from simple steatosis …